BACKGROUND: Human chorionic gonadotropin (hCG) is normally produced and secreted by trophoblastic cells during pregnancy and from gestational trophoblastic neoplasms. It is also detected in ovarian, stomach, and colon adenocarcinomas, as well as in squamous cell carcinoma of the oesophagus. Recently, interest in its role in the pathogenesis of tumours has been enlivened after the presence of beta hCG in the cell membrane of several malignant cells was shown in vitro. AIMS: To investigate the circulating concentrations of beta hCG in patients with exocrine pancreatic adenocarcinoma and to examine its potential prognostic value. PATIENTS: Thirty six patients with exocrine pancreatic adenocarcinoma, 12 patients with chronic pancreatitis, and 21 healthy volunteers were studied. METHODS: beta hCG serum concentrations were detected by the application of a radioimmunoassay technique. RESULTS: Fifteen of 36 patients with pancreatic adenocarcinoma and only one patient with chronic pancreatitis had detectable plasma concentrations of beta hCG (p < 0.01). The patients with circulating serum titres of beta hCG had a worse outcome compared with the group of beta hCG negative patients: the difference was statistically significant (p = 0.01). CONCLUSION: More than 40% of pancreatic exocrine tumours produce beta hCG and its production is correlated with an adverse effect on outcome.
BACKGROUND:Human chorionic gonadotropin (hCG) is normally produced and secreted by trophoblastic cells during pregnancy and from gestational trophoblastic neoplasms. It is also detected in ovarian, stomach, and colon adenocarcinomas, as well as in squamous cell carcinoma of the oesophagus. Recently, interest in its role in the pathogenesis of tumours has been enlivened after the presence of beta hCG in the cell membrane of several malignant cells was shown in vitro. AIMS: To investigate the circulating concentrations of beta hCG in patients with exocrine pancreatic adenocarcinoma and to examine its potential prognostic value. PATIENTS: Thirty six patients with exocrine pancreatic adenocarcinoma, 12 patients with chronic pancreatitis, and 21 healthy volunteers were studied. METHODS: beta hCG serum concentrations were detected by the application of a radioimmunoassay technique. RESULTS: Fifteen of 36 patients with pancreatic adenocarcinoma and only one patient with chronic pancreatitis had detectable plasma concentrations of beta hCG (p < 0.01). The patients with circulating serum titres of beta hCG had a worse outcome compared with the group of beta hCG negative patients: the difference was statistically significant (p = 0.01). CONCLUSION: More than 40% of pancreatic exocrine tumours produce beta hCG and its production is correlated with an adverse effect on outcome.
Authors: Michael A Morse; Robert Chapman; John Powderly; Kimberly Blackwell; Tibor Keler; Jennifer Green; Renee Riggs; Li-Zhen He; Venky Ramakrishna; Laura Vitale; Biwei Zhao; Stephen A Butler; Amy Hobeika; Takuya Osada; Thomas Davis; Timothy Clay; H Kim Lyerly Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Paul M Doyle; Waziq A Thiryayi; Abhijit Joshi; Daniel du Plessis; Tara Kearney; Kanna K Gnanalingham Journal: Pituitary Date: 2009 Impact factor: 4.107
Authors: Brian M Nolen; Randall E Brand; Denise Prosser; Liudmila Velikokhatnaya; Peter J Allen; Herbert J Zeh; William E Grizzle; Ying Huang; Aleksey Lomakin; Anna E Lokshin Journal: PLoS One Date: 2014-04-18 Impact factor: 3.240